Laboratory Values of the Patient during the Course of Treatment
| Component | First Admission | Second Admission | After Methotrexate | Reference Range |
|---|---|---|---|---|
| WBC (k/UI) | 15.8 | 18.1 | 10.7 | 5.5–13 |
| Hemoglobin (g/dL) | 11.3 | 8.9 | 14.4 | 13.2–15.6 |
| Hematocrit (%) | 34.2 | 27.8 | 45.8 | 41–53 |
| Platelet (k/ul) | 253 | 558 | 235 | 150–400 |
| Neutrophils (%) | 60 | 41 | 67 | 28–78 |
| Bands (%) | 27 | 36 | 0 | <10 |
| C-reactive protein (mg/dL) | 16 | 17.6 | <0.5 | <0.9 |
| Erythrocyte sedimentation rate (mm/hr) | 79 | 121 | 1 | <16 |
| Total protein (g/dL) | 5.5 | 6.8 | 6.6 | 6.2–8.3 |
| Albumin (g/dL) | 2 | 2.3 | 4.1 | 3.4–4.8 |
| Bilirubin, direct (mg/dL) | 1.2 | 1 | 0.2 | 0.1–0.3 |
| Bilirubin total (g/dL) | 2.5 | 2.1 | 1.1 | 0.1–1.5 |
| Alkaline phosphatase (IU/L) | 262 | 291 | 89 | 50–190 |
| ALT (IU/L) | 143 | 142 | 42 | 7–40 |
| AST (IU/L) | 141 | 138 | 15 | 7–40 |
| INR | 1.3 | 1.3 | 0.9–1.1 | |
| Prothrombin time (sec) | 14.4 | 15.2 | 10–12.5 | |
| LDH (U/L) | Not done | 416 | Not done | 50–220 |
| Ferritin (ng/mL) | Not done | 46709.9 | 431.6 | 11.5–300 |
| HIV | Negative | – | – | Negative |
| Cytomegalovirus | Negative | – | – | Negative |
| ANA | Negative | – | – | Negative |
| RF | Negative | – | – | Negative |
| ASO titer (IU) | Not done | 177 | – | <133 |
| EBV VCA Ig M | Positive | Negative | – | Negative |
| EBV VCA Ig G | Positive | Positive | – | Negative |
| EBV early antigen | Negative | Equivocal | – | Negative |
| EBV nuclear antigen | Negative | Negative | – | Negative |
| Mycoplasma IgG AB | Positive | Positive | – | Negative |
| Mycoplasma IgM AB | Positive | Negative | – | Negative |
WBC, white blood cell; ALT, alanine amino transaminase; AST, aspartate aminotransferase; INR, international normalized ratio; LDH, lactic dehydroginase level; HIV, human immunodeficiency virus; ANA, antinuclear antibody; RF, rheumatoid factor; ASO, antistreptolysin O; EBV, Epstein-Barr virus; VCA, viral capsid antigen; Ig, immunoglobulin; AB, antibody.